Closing a door

Catheterization and Cardiovascular Interventions

Volumn 71, Issue 3, 2008, Pages 396-397

  Butman, Samuel ^a,b  

^a Verde Valley Heart Center

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICKEL; NITINOL; WARFARIN;

ALLERGIC REACTION; ANTICOAGULATION; CATHETER ABLATION; DECOMPRESSION SICKNESS; ELECTROCARDIOGRAM; EMBOLISM; ENDOCARDITIS; HEART ARRHYTHMIA; HUMAN; MEDICAL INSTRUMENTATION; MIGRAINE; NOTE; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; STROKE; SUPRAVENTRICULAR TACHYCARDIA; THROMBUS;

BALLOON OCCLUSION; FEMALE; FORAMEN OVALE, PATENT; HEART CATHETERIZATION; HUMANS; MALE; PROGNOSIS; PROSTHESIS DESIGN; PROSTHESIS IMPLANTATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 41149106978     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21496     Document Type: Note

References (6)

1. Donti A, Giardini A, Salomone L, Formigari R, Picchio FM. Transcatheter patent foramen ovale closure using the premere PFO occlusion system. Catheter Cardiovasc Interv 2006;68:736-740.
2. Sievert H, Babic UU, Hausdorf G, Schneider M, Hopp HW, Pfeiffer D, Pfisterer M, Friedli B, Urban P. Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial). Am J Cardiol 1998; 82:1405-1413.
3. Chatterjee T, Petzsch M, Ince H, Rehders TC, Korber T, Weber F, Schneider Huf der MC, Nienaber CA. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 2005;18: 173-179.
4. Spies C, Timmermanns I, Reissmann U, Essen JV, Schräder R. Patent foramen ovale closure with the Intrasept occluder: Complete 6 to 56 months follow-up of 247 patients after presumed paradoxical embolism. Catheter Cardiovasc Interv 2008;71:290-295.
5. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, Sievert H. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43:302-309.
6. Mullen MJ, Hildick-Smith D, De Giovanni JV, Duke C, Hillis WS, Morrison WL, Jux C. BioSTAR Evaluation STudy (BEST): A prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 2006;114:1962-1967.